Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Glenmark Life Sciences has reported total income of Rs. 594.109 crores during the period ended June 30, 2024
_256_384.jpg)
Glenmark released Picture Post Cards on World Vitiligo Day
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
Subscribe To Our Newsletter & Stay Updated
